

## Drug Monograph

Drug Name: **Trudhesa™ (dihydroergotamine mesylate) nasal spray**  
 Drug Class: **Central Nervous System: Anti-migraine, Ergotamine Derivatives**  
 Prepared For: MO HealthNet  
 Prepared By: Conduent

☒ **New Criteria**

☐ **Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Trudhesa is packaged with 4 single-dose units, each unit contains 4mg of dihydroergotamine mesylate in 1 mL of solution and includes a nasal spray device.

**Manufacturer:** Distributed by: Impel NeuroPharma Inc., Seattle, WA 98119.

**Indications:** Trudhesa is indicated for the acute treatment of migraine with or without aura in adults.

**Costs:** \$848 per 4-dose package. Wholesale Acquisition Cost

**Summary of Findings:** The MO HealthNet Division recommends prior authorization status for this product.

**Status Recommendation:**

<input type="checkbox"/> Clinical Edit	<input checked="" type="checkbox"/> PA Required
<input type="checkbox"/> Open Access	<input type="checkbox"/> PDL

**Type of PA Criteria:**

<input checked="" type="checkbox"/> Appropriate Indications	<input type="checkbox"/> Non-Preferred
<input type="checkbox"/> No PA Required	<input type="checkbox"/> Preferred

Prepared by: April Ash, PharmD  
 Date: February 10, 2022